用于zeptomole水平超灵敏检测阿尔茨海默病生物标志物的光触发石墨烯/黑磷异质结构场效应晶体管平台。
Light-Triggered Graphene/Black Phosphorus Heterostructure FET Platform for Ultrasensitive Detection of Alzheimer's Disease Biomarkers at the Zeptomole Level.
作者信息
Wang Huide, Qiu Meng, Wang Chen, Zhang Liding, Fan Ning, Chen Zhi, Liu Yi, Li Tianzhong, Wang Ziqian, Zhu Yihan, Zhang Yule, Tian Xilin, Wang Yun, Yang Mingmin, Fan Dianyuan, Luo Qingming, Jiang Ke, Luo Haiming, Zhang Han
机构信息
State Key Laboratory of Radio frequency Heterogeneous integration, International Collaborative Laboratory of 2D Materials for Optoelectronics Science and Technology, Institute for Advanced Study in Nuclear Energy & Safety, Interdisciplinary Center of High Magnetic Field Physics of Shenzhen University, College of Physics and Optoelectronic Engineering, Shenzhen University, Shenzhen, China.
Key Laboratory of Marine Chemistry Theory and Technology (Ministry of Education), College of Chemistry and Chemical Engineering, Ocean University of China, Qingdao, China.
出版信息
Research (Wash D C). 2025 Aug 14;8:0772. doi: 10.34133/research.0772. eCollection 2025.
Due to the low concentration of amyloid-beta (Aβ) in plasma and the high content of interfering factors, the conventional detection method for the quantification of Aβ still faces the problem of insufficient limit of detection (LOD). In this work, we propose a new light-triggered graphene-black phosphorus heterostructure (G-BP) field-effect transistor (FET) biosensing platform that achieves a marked reduction in the LOD. The LOD for Alzheimer's disease (AD) biomarker Aβ detection using the G-BP FET is as low as 235.1 zM (2.351 × 10 M), which is the lowest value reported to date and is approximately 2 to 3 orders of magnitude lower than other reported biosensing platforms. The G-BP FET platform provides precise, real-time guidance for non-invasive early diagnosis, disease monitoring, and personalized treatment plans for AD. Moreover, this method has good scalability and potential applications in other areas, including early detection of cancer and other major chronic diseases.
由于血浆中β-淀粉样蛋白（Aβ）浓度较低且干扰因素含量较高，用于定量Aβ的传统检测方法仍面临检测限（LOD）不足的问题。在这项工作中，我们提出了一种新型的光触发石墨烯-黑磷异质结构（G-BP）场效应晶体管（FET）生物传感平台，该平台实现了检测限的显著降低。使用G-BP FET检测阿尔茨海默病（AD）生物标志物Aβ的检测限低至235.1 zM（2.351×10⁻¹⁹ M），这是迄今为止报道的最低值，比其他报道的生物传感平台低约2至3个数量级。G-BP FET平台为AD的非侵入性早期诊断、疾病监测和个性化治疗方案提供了精确的实时指导。此外，该方法具有良好的可扩展性，并在其他领域具有潜在应用，包括癌症和其他重大慢性病的早期检测。
Zotero 插件